Anhui Anke Biotechnology Group Co Ltd
SZSE:300009

Watchlist Manager
Anhui Anke Biotechnology Group Co Ltd Logo
Anhui Anke Biotechnology Group Co Ltd
SZSE:300009
Watchlist
Price: 10.03 CNY Market Closed
Market Cap: 16.8B CNY

Anhui Anke Biotechnology Group Co Ltd
Tax Provision

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Anhui Anke Biotechnology Group Co Ltd
Tax Provision Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Tax Provision CAGR 3Y CAGR 5Y CAGR 10Y
Anhui Anke Biotechnology Group Co Ltd
SZSE:300009
Tax Provision
-ÂĄ74.9m
CAGR 3-Years
14%
CAGR 5-Years
-2%
CAGR 10-Years
-12%
Beigene Ltd
HKEX:6160
Tax Provision
-ÂĄ815.6m
CAGR 3-Years
-69%
CAGR 5-Years
-36%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Tax Provision
-ÂĄ78.8m
CAGR 3-Years
-27%
CAGR 5-Years
-86%
CAGR 10-Years
N/A
Akeso Inc
HKEX:9926
Tax Provision
ÂĄ0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Tax Provision
ÂĄ41.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
S
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
HKEX:6990
Tax Provision
-ÂĄ124.2m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Anhui Anke Biotechnology Group Co Ltd
Glance View

Market Cap
16.8B CNY
Industry
Biotechnology

Anhui Anke Biotechnology Group Co., Ltd., nestled in the heart of China's Anhui Province, weaves a story that blends innovation with a commitment to health. Founded in 1986, Anke Biotechnology made its mark early by focusing on the development and manufacturing of biopharmaceutical products. The company's narrative is rooted in its pursuit of cutting-edge technology, specifically in the fields of genetic engineering, fermentation technology, and vaccine production. As China looks to bolster its biopharmaceutical sector, Anke stands out with its robust pipeline of recombinant protein drugs and vaccines that cater to widespread public health needs. By leveraging advanced bioengineering processes, the company aims to encapsulate scientific complexity into tangible, life-saving treatments. At the core of its operations is a diverse business model that spans research, development, production, and commercialization of healthcare products. Through strategic alliances and continuous investment in R&D, Anke Biotechnology sustains a competitive edge by bringing innovative therapies to market. Revenue flows from its flagship products like recombinant human growth hormones and interferons, which address critical healthcare demands not just within China, but internationally as well. Furthermore, the company astutely capitalizes on the rising healthcare needs of an aging population, along with the increasing importance of preventive medicine, reflected in its vaccine offerings. It’s this strategic acumen, blended with scientific prowess, that allows Anhui Anke Biotechnology to thrive in an industry characterized by rapid innovation and evolving challenges.

Intrinsic Value
11.71 CNY
Undervaluation 14%
Intrinsic Value
Price

See Also

What is Anhui Anke Biotechnology Group Co Ltd's Tax Provision?
Tax Provision
-74.9m CNY

Based on the financial report for Sep 30, 2025, Anhui Anke Biotechnology Group Co Ltd's Tax Provision amounts to -74.9m CNY.

What is Anhui Anke Biotechnology Group Co Ltd's Tax Provision growth rate?
Tax Provision CAGR 10Y
-12%

Over the last year, the Tax Provision growth was -32%. The average annual Tax Provision growth rates for Anhui Anke Biotechnology Group Co Ltd have been 14% over the past three years , -2% over the past five years , and -12% over the past ten years .

Back to Top